Suggestions
Michael Palfreyman
Chief R&D Officer at Cybin Inc.
Michael Palfreyman, Ph.D., is a seasoned professional in the biopharmaceutical industry with extensive experience in drug discovery and development.23 He recently served as the Chief Research & Development Officer at Cybin Inc., a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health conditions.14
Career Highlights
Expertise:: Dr. Palfreyman has over 30 years of preclinical and clinical development experience, having worked with various pharmaceutical and biotechnology companies including Scriptgen, EnVivo Pharma, Sanofi, and GSK.2
Leadership Roles:: Throughout his career, he has held several leadership positions, guiding biopharmaceutical startups through clinical proof of concept stages.5
Recent Transition:: As of June 5, 2023, Dr. Palfreyman transitioned from his role as Chief R&D Officer at Cybin to an advisory position.1 This change followed the achievement of key milestones related to Cybin's acquisition of Adelia Therapeutics, which helped advance the company's psychedelic programs from laboratory research to clinical trials.1
Contributions at Cybin
During his tenure at Cybin, Dr. Palfreyman played a crucial role in:
- Advancing research and development pipelines
- Discovering potential new drug formulations and delivery methods
- Creating clinical protocols for psychedelic compounds
- Supporting the clinical-stage development of CYB003 and CYB004 programs for major depressive disorder (MDD) and generalized anxiety disorder (GAD), respectively
- Building a robust intellectual property portfolio, with over 50 granted or pending patent applications across 6 patent families1
Dr. Palfreyman's work has significantly contributed to Cybin's transition from a discovery-stage to a clinical-stage development organization, furthering the company's mission to revolutionize mental healthcare through innovative psychedelic-based treatment options.1